Solutions for Metabolic Symbiosis Between TMEs and Tumor Cells
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology is committed to providing global collaborators with a full range of solutions and services to study the metabolic symbiosis of tumor microenvironment (TME) and tumor cells, to help you successfully achieve your research goals.
The existence of metabolic symbiosis in tumors, where cells in the oxygen-depleted zone can take up lactic acid produced by glycolysis and enter the tricarboxylic acid cycle to produce ATP, reflects Darwin's theory of biological evolution. The lactic acid produced by glycolysis in the oxygen-depleted zone is taken up and used by cells in the oxygen-rich zone, allowing cells in both environments to survive. Tumor metabolic symbiosis is formed by the selection of tumor cells to adapt to the harsh surrounding survival environment. The existence of metabolic symbiosis has been confirmed in several tumors, such as lung cancer, gastric cancer, breast cancer, prostate cancer, head and neck tumors. Studies have shown that metabolic symbiosis plays an important role in tumor cell apoptosis, tumor angiogenesis, and tumor stem cells, and preliminary studies suggest that metabolic symbiosis is closely related to tumor treatment resistance and poor prognosis. A full understanding of tumor metabolic symbiosis in tumor microenvironment (TME) will be useful for designing new and efficient therapeutic strategies.
Given that metabolic symbiosis is closely related to tumor cell characteristics, treatment resistance and poor prognosis, targeted interference with metabolic symbiosis may be a direction for future development of tumor therapeutics and deserves further investigation. Alfa Oncology has established an innovative technology platform for the tumor microenvironment center and is developing a variety of technologies to provide high quality solutions and services to our global collaborators. We design scientific experiments to help provide new insights into metabolic symbiosis in tumors and microenvironments, reveal the molecular mechanisms of metabolic symbiosis, and provide new approaches to predict tumor prognosis and treatment.
Using metabolomics technology, Alfa Oncology will monitor the symbiotic effects of metabolites in the specific tumor microenvironment and the effects on apoptosis, tumor angiogenesis, and tumor stem cells. By obtaining metabolic profiles of metabolites and determining the biological effects of metabolite changes, we will help to understand the metabolic symbiosis in the tumor and microenvironment and to study its molecular mechanisms in depth. We provide services related to this biological problem, such as target metabolite analysis, metabolite fingerprinting, metabolic profiling, metabolite characterization and quantification.
Single-cell metabolomics distinguishes individual cell types in the tumor microenvironment (TME) and reveals their respective metabolic profiles and metabolic symbiosis. While single-cell metabolomics truly has very large metabolite coverage and allows for more rapid identification while enabling high-throughput detection. It is expected to be one of the most effective tools for metabolic symbiosis studies of various cell types in the tumor microenvironment (TME).
As one of the world's leading companies in the field of tumor microenvironment (TME) research, Alfa Oncology is committed to supporting researchers in making groundbreaking scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. With years of experience in the field of TME, we are ready to provide reliable solutions and quality services to our customers. If you have any special needs or questions, please feel free to contact us for support from our experienced experts.